in accordance with amendments to SEBI (LODR) (third amendment) Regulations, 2024 read with SEBI circular No. SEBI/HO/CFD/CFD-PoD2/ CIR/P/2024/185 dated 31.12.2024. the integrated filing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma's revenue from operations surged about 155% YoY to Rs. 28.20 crore in FY25 from Rs. 11.05 crore in FY24, while Q4 FY25 revenue rose to Rs. 4.83 crore from Rs. 4.26 crore a year ago. Despite the strong top-line, the company remained in the red with a net loss of Rs. 2.09 crore in FY25, although the loss narrowed sharply from Rs. 5.75 crore in FY24. The P&L includes an exceptional item of Rs. 1.07 crore representing loss on assets damaged in a December 2023 factory fire. The auditor issued a qualified opinion, flagging (a) Rs. 3.69 crore booked as expenditure related to the fire still shown under current assets with no formal insurance claim lodged, and (b) a Rs. 40 lakh mutual fund investment made in the name of the Managing Director, which contravenes Section 187(1) of the Companies Act. Total equity turned negative at Rs. -1.99 crore, and operating cash flow remained negative at Rs. -65.6 lakh, with cash balances of just Rs. 9 lakh at year-end.
While revenue growth is a positive, the negative net worth, persistent losses, qualified audit report, and negative operating cash flow raise serious going-concern doubts. Shareholders should treat this as a high-risk situation; near-term stock performance is likely to remain weak pending clarity on insurance recovery, resolution of the Section 187 violation, and improvement in cash flows.